REFERENCES
- Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratana-suwan W, Kovacs C. Sustained antiretroviral efficacy of raltegravir as part of combination antiretroviral therapy in treatment-naive HIV-1 infected patients: 96-week data. J Acquir Immune Defic Syndr. 2008;52:350–356.
- Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–354.
- Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infec-tion. N Engl J Med. 2008;359:355–365.
- Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796–806.
- Lennox JL, DeJesus E, Berger DS, et al. Raltegravir ver-sus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010;55:39–48.
- Rockstroh JK, Lennox JL, DeJesus E, et al. Long-term treatment with raltegravir or efavirenz combined with teno-fovir/emtricitabine for treatment-naive human immunode-ficiency virus-1—infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53:807–816.
- Department of Health and Human Services Panel-Office of AIDS Research Advisory Council. Guidelines for the use of antiretroviral agents in HIV-infected adults and adoles-cents. 2011. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed September 19, 2011.